Tokarek Julita, Budny Emilian, Saar Maciej, Stańczak Kamila, Wojtanowska Ewa, Młynarska Ewelina, Rysz Jacek, Franczyk Beata
Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Biomedicines. 2023 Sep 23;11(10):2611. doi: 10.3390/biomedicines11102611.
Cardiovascular diseases and diabetes mellitus are currently among the diseases with the highest morbidity and mortality. The pathogenesis and development of these diseases remain strongly connected, along with inflammation playing a major role. Therefore, the treatment possibilities showing a positive impact on both of these diseases could be especially beneficial for patients. SGLT-2 inhibitors and GLP-1 receptor agonists present this dual effect. Moreover, the hostile composition of the gut microbiota could influence the progression of these conditions. In this review, the authors present the latest knowledge on and innovations in diabetes mellitus and CVD-with the focus on the molecular mechanisms and the role of the microbiota.
心血管疾病和糖尿病目前是发病率和死亡率最高的疾病之一。这些疾病的发病机制和发展仍然紧密相连，炎症在其中起着主要作用。因此，对这两种疾病都有积极影响的治疗方法可能对患者特别有益。钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂具有这种双重作用。此外，肠道微生物群的不良组成可能会影响这些疾病的进展。在这篇综述中，作者介绍了糖尿病和心血管疾病的最新知识和创新——重点是分子机制和微生物群的作用。
